骨髓刺激后骨髓干细胞移植治疗肢体缺血性疾病的基础与临床研究
|
摘要
目的:
观察骨髓刺激后骨髓源干细胞移植治疗肢体缺血性疾病的疗效;探讨骨髓刺激后自体骨髓源干细胞移植治疗肢体缺血性疾病的机制。
研究方法:
本研究分为三部分。第一部分为骨髓刺激后骨髓源干细胞移植治疗肢体缺血性疾病的基础研究,在动物模型上比较骨髓刺激与非刺激骨髓源干细胞移植后对动物缺血肢体血流重建的影响,并探讨其作用机制,为临床研究提供理论基础;第二部分和第三部分分别为骨髓刺激后骨髓源干细胞移植治疗下肢动脉硬化闭塞症和血栓闭塞性脉管炎的临床研究,从临床角度观察骨髓刺激后骨髓源干细胞移植对缺血肢体血流重建的影响。
结果:
基础研究:
1、骨髓刺激组迁移细胞数目明显多于骨髓未刺激组;骨髓刺激组黏附细胞数目明显多于骨髓未刺激组。
2、行骨髓源内皮祖细胞移植的骨髓刺激组侧支血管数目、CD31阳性细胞数目、肢体血流百分比的增加和VEGFmRNA表达水平明显多于骨髓未刺激组。
临床研究:
1、在抽取骨髓血量接近的情况下,骨髓刺激组获取的细胞数明显多于骨髓未刺激组。
2、骨髓刺激组移植细胞中CD34+细胞所占比例明显高于骨髓未刺激组。
3、骨髓刺激组较骨髓未刺激组主观症状及部分客观指标有明显改善。
结论:
1、骨髓刺激后骨髓源干细胞移植对下肢动脉硬化闭塞症和血栓闭塞性脉管炎患者肢体缺血的改善优于未刺激的骨髓源干细胞移植。
2、骨髓刺激提高骨髓源干细胞移植改善肢体缺血疗效的机制可能是骨髓源内皮祖细胞数量的增加和功能的改善。
3、骨髓刺激后骨髓源干细胞移植是传统骨髓干细胞移植治疗肢体缺血性疾病方案的补充和优化。
Objectives:
We observed the effectiveness of bone marrow stem cells transplantation to treat the limb ischemic diseases after the bone marrow stimulation and researched the mechanism of bone marrow stem cells transplantation to treat the limb ischemic diseases after the bone marrow stimulation.
Methods:
Three parts were consisted of this research. The part 1 was focus on the experimental research of bone marrow stem cells transplantation to treat the limb ischemic disease after the bone marrow stimulation. In this part, the effectiveness of bone marrow stem cells transplantation on the animal models with the bone marrow stimulation were compared with the animal models without the bone marrow stimulation. The results of this part provided the theoretic basis for the clinical research. The part 2 and the part 3 were the clinical researches of bone marrow stem cells transplantation for the treatment of Arteriosclerosis Obliterans(ASO) and Thromboangiitis Obliterans(TAO) after the bone marrow stimulation respectively.
Results:
Experimental research:
1 The number of migrating and adhering cells in the bone marrow stimulating group were significantly increased in comparison with the non-stimulating group.
2 The number of collateral branches of the vessel, CD31 positive cells and the expressing level of VEGFmRNA in the bone marrow stimulating group were significantly increased in comparison with the non-stimulating group.
Clinical research:
1 The number of Bone Marrow-Mononuclear Cells (BM-MNCs) in the bone marrow stimulating group was significantly higher than it in the non-stimulating group under obtaining the similar volume of the bone marrow blood.
2 The percent of CD34 positive cells in the bone marrow stimulating group was significantly higher than it in the non-stimulating group
3 The symptoms and the part of objective indexs in the bone marrow stimulating group were significantly improved in comparison with the non-stimulating group.
Conclusions:
1 The capabilities of revascularization after the bone marrow stem cells transplantation in the bone marrow stimulating group were obviously superior to the capabilities of revascularization in the non-stimulating group for the treatment of ASO and TAO.
2 The mechanisms of bone marrow stem cells transplantation after the bone marrow stimulation for the treatment of the lower limb ischemia may be the increasing of endothelial progenitor cells’(EPCs)number and the improvement of EPCs’functions.
3、Bone marrow stem cells transplantation after the bone marrow stimulation is a supplement and optimization of the traditional bone marrow stem cells transplantation for the treatment of the limb ischemic diseases.
观察骨髓刺激后骨髓源干细胞移植治疗肢体缺血性疾病的疗效;探讨骨髓刺激后自体骨髓源干细胞移植治疗肢体缺血性疾病的机制。
研究方法:
本研究分为三部分。第一部分为骨髓刺激后骨髓源干细胞移植治疗肢体缺血性疾病的基础研究,在动物模型上比较骨髓刺激与非刺激骨髓源干细胞移植后对动物缺血肢体血流重建的影响,并探讨其作用机制,为临床研究提供理论基础;第二部分和第三部分分别为骨髓刺激后骨髓源干细胞移植治疗下肢动脉硬化闭塞症和血栓闭塞性脉管炎的临床研究,从临床角度观察骨髓刺激后骨髓源干细胞移植对缺血肢体血流重建的影响。
结果:
基础研究:
1、骨髓刺激组迁移细胞数目明显多于骨髓未刺激组;骨髓刺激组黏附细胞数目明显多于骨髓未刺激组。
2、行骨髓源内皮祖细胞移植的骨髓刺激组侧支血管数目、CD31阳性细胞数目、肢体血流百分比的增加和VEGFmRNA表达水平明显多于骨髓未刺激组。
临床研究:
1、在抽取骨髓血量接近的情况下,骨髓刺激组获取的细胞数明显多于骨髓未刺激组。
2、骨髓刺激组移植细胞中CD34+细胞所占比例明显高于骨髓未刺激组。
3、骨髓刺激组较骨髓未刺激组主观症状及部分客观指标有明显改善。
结论:
1、骨髓刺激后骨髓源干细胞移植对下肢动脉硬化闭塞症和血栓闭塞性脉管炎患者肢体缺血的改善优于未刺激的骨髓源干细胞移植。
2、骨髓刺激提高骨髓源干细胞移植改善肢体缺血疗效的机制可能是骨髓源内皮祖细胞数量的增加和功能的改善。
3、骨髓刺激后骨髓源干细胞移植是传统骨髓干细胞移植治疗肢体缺血性疾病方案的补充和优化。
Objectives:
We observed the effectiveness of bone marrow stem cells transplantation to treat the limb ischemic diseases after the bone marrow stimulation and researched the mechanism of bone marrow stem cells transplantation to treat the limb ischemic diseases after the bone marrow stimulation.
Methods:
Three parts were consisted of this research. The part 1 was focus on the experimental research of bone marrow stem cells transplantation to treat the limb ischemic disease after the bone marrow stimulation. In this part, the effectiveness of bone marrow stem cells transplantation on the animal models with the bone marrow stimulation were compared with the animal models without the bone marrow stimulation. The results of this part provided the theoretic basis for the clinical research. The part 2 and the part 3 were the clinical researches of bone marrow stem cells transplantation for the treatment of Arteriosclerosis Obliterans(ASO) and Thromboangiitis Obliterans(TAO) after the bone marrow stimulation respectively.
Results:
Experimental research:
1 The number of migrating and adhering cells in the bone marrow stimulating group were significantly increased in comparison with the non-stimulating group.
2 The number of collateral branches of the vessel, CD31 positive cells and the expressing level of VEGFmRNA in the bone marrow stimulating group were significantly increased in comparison with the non-stimulating group.
Clinical research:
1 The number of Bone Marrow-Mononuclear Cells (BM-MNCs) in the bone marrow stimulating group was significantly higher than it in the non-stimulating group under obtaining the similar volume of the bone marrow blood.
2 The percent of CD34 positive cells in the bone marrow stimulating group was significantly higher than it in the non-stimulating group
3 The symptoms and the part of objective indexs in the bone marrow stimulating group were significantly improved in comparison with the non-stimulating group.
Conclusions:
1 The capabilities of revascularization after the bone marrow stem cells transplantation in the bone marrow stimulating group were obviously superior to the capabilities of revascularization in the non-stimulating group for the treatment of ASO and TAO.
2 The mechanisms of bone marrow stem cells transplantation after the bone marrow stimulation for the treatment of the lower limb ischemia may be the increasing of endothelial progenitor cells’(EPCs)number and the improvement of EPCs’functions.
3、Bone marrow stem cells transplantation after the bone marrow stimulation is a supplement and optimization of the traditional bone marrow stem cells transplantation for the treatment of the limb ischemic diseases.
引文
1. Joseph Emmerich. Current State and Perspective on Medical Treatment of Critical Leg ischemia: Gene and Cell Therapy. International Journal of Lower Extremity Wounds,2005, 4: 234-241
2. Li G, Hu Y, Yang W, et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the DA Qing IGT and Diabetes Study. Diabetes Res Clin Pract., 2002,58:193-200.
3.范丽凤,陆菊明,郑亚光,等.糖尿病患者足溃疡的危险因素分析.中华糖尿病杂志, 2006, 14:435-437
4. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. Trans Atlantic Inter-Society Concensus (TASC). J Vasc Surg, 2000,31:S1-S296.
5. Lu D, Chen B, Liang Z, et al. Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double-blind, randomized, controlled trial.Diabetes Res Clin Pract. 2011,92:26-36.
6. Walter DH, Krankenberg H, Balzer JO, et al. Intraarterial administration of bone marrow mononuclear cells in patients with critical limb ischemia: a randomized-start, placebo-controlled pilot trial (PROVASA).Circ Cardiovasc Interv. 2011, 4:26-37.
7. Cobellis G, Botti C, Taddeo A, et al. Successful bone marrow transplantation reveals the lack of endothelial progenitor cells mobilization in a patient with critical limb ischemia: a case report. Transplant Proc. 2010 , 42:2816-2820.
8. Meng J, Yao X, Kang S, et al. Treatment of ischemic limbs by transplantation of G-CSF stimulated bone marrow cells in diabetic rabbits.Clin Invest Med. 2010, 33:E174-180.
9. Onodera R, Teramukai S, Tanaka S, et al. Bone marrow mononuclear cells versus G-CSF-mobilized peripheral blood mononuclear cells for treatment of lower limb ASO: pooled analysis for long-term prognosis.Bone Marrow Transplant. 2011, 46:278-284.
10. Sacramento CB, da Silva FH, Nardi NB, et al. Synergistic effect of vascular endothelial growth factor and granulocyte colony-stimulating factor double gene therapy in mouse limb ischemia. J Gene Med. 2010 , 12:310-319.
11. Horie T, Onodera R, Akamastu M, et al. Long-term clinical outcomes for patients withlower limb ischemia implanted with G-CSF-mobilized autologous peripheral blood mononuclear cells. Atherosclerosis. 2010 , 208:461-466.
12. Kawamoto A, Katayama M, Handa N, et al. Intramuscular transplantation of G-CSF-mobilized CD34(+) cells in patients with critical limb ischemia: a phase I/IIa, multicenter, single-blinded, dose-escalation clinical trial. Stem Cells. 2009, 27:2857-2864
1. Kanako M, Takashi S, Chiaka K, et al. Changes of mRNA Expression of Vascular Endothelial Growth Factor, Angiopoietins and Their Receptors During the Periovulatory Period in eCG/hCG-Treated Immature Female Rats. J. Exp. Zool, 2005, 303A: 590– 597
2. TateishiYuyama E, M atsubara H, M urohara T, et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomized controled trial. Lancet, 2002, 360 ( 9331) : 427-435.
3.谷涌泉,郭连瑞,张建,等.自体骨髓源干细胞移植治疗严重下肢缺血1例.中国实用外科杂志, 2003, 23 (11) : 670-670.
4.谷涌泉,张建,郭连瑞,等.骨髓动员刺激后自体骨髓源单个核细胞移植治疗下肢缺血的初步临床研究.中国修复重建外科杂志, 2006, 20(10):1017-1020.
5. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative endothelial progenitor cells for angiogenesis. Science, 1997, 275(5302): 964-967.
6. Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular function and cardiovascular risk.. N Engl J Med, 2003, 348(7): 593-600.
7. Lachmann N, Nikol S. Therapeutic angiogenesis for peripheral artery disease: stem cell therapy.Vasa, 2007, 36(4):241-251.
8. KIM, KIM, JOH, et. Angiogenesis Facilitated by Autologous Whole Bone Marrow Stem Cell Transplantation for Buerger’s Disease. StemCells ,2006,24:1194-1200;
9. Iba O, Matsubara H, Nozawa Y, Fujiyama S, Amano K, Mori Y, et al. Angiogenesis by implantation of peripheral blood mononuclear cells and platelets into ischemic limbs. Circulation,2002,106: 2019–2025.
10. Silvestre JS, Mallat Z,Duriez M,et al. Antiangiogenic effect of interleukin-10 in ischemia-induced angiogenesis in mice hindlimb. Circulation research,2000,87:448-52
1.李学东;陈剑秋.下肢动脉硬化闭塞症的腔内治疗.医学综述, 2010, 16: 882-884
2. Hoshino J, Ubara Y, Hara S, et al. Quality of life improvement and long-term effects of peripheral blood mononuclear cell transplantation for severe arteriosclerosis obliterans in diabetic patients on dialysis.Circ J. 2007, 71:1193-1198
3. Lawall H, Bramlage P, Amann B. Treatment of peripheral arterial disease using stem and progenitor cell therapy.J Vasc Surg. 2011 ,53:445-453.
4.谷涌泉,郭连瑞,张建,等.自体骨髓干细胞移植治疗严重下肢缺血1例.中国实用外科杂志2003,23:670
5. Selvin E, Erlinger T. Prevalence and risk factors for peripheral arterial disease in the Unites States: results from the national Health and Nutrition Examination Survery, 1999-2000[J].Circulation, 2004;110(6):734-738
6.李小鹰,王洁,王全义,等.周围动脉硬化闭塞症在老年血脂异常人群中的现病率调查[J].中华老年心胸血管病杂志,2005;7(1):3-6
7.刘昌伟.下肢动脉硬化闭塞症的外科治疗.临床外科杂志,2006,14(5):265-266
8. Mamode N, Scott RN. Graft type for femoro-popliteal bypass surgery[J].Cochrance Database syst Rev, 2000,(2):CD001487
9. Devine C, McCollum C. North West femoro-popliteal trial participants heparin-bonded dacron or polytetrafluorethylene for femoropopliteal bypass: five-year results of a prospective randomized multicenter clinical trial[J]. J Vasc Surg, 2004,40(5):924-931
10. Surowiec SM, Davies MG, Ebery SW, et al. Percutaneous angioplasty and stenting of the superficial femoral artery[J].J vasc surg, 2005,41(2):269-278
11. Tomita S,Mickle DA,Weisel RD,et al.Improved heart function with myogenesis and angiogenesis after autologouse porcine bone marrow stromal cell transplantation [J].J Thorac cardiovasc surg,2002,123(6):1132—1140
12. Orlic D, Kajstura j, Chimenti S, et al. Bone marrow cells regenerate infarcted myocardium[J].Nature, 2001, 410(6829):70l-705.
13. Jiang Y,Jahagirdar BN,Reinhardt RL,et a1.Pluripotency of mesenchymal stem cells derived from adult marrow[J].Nature,2002,418(6893):41-49.
14.周斌,李抒,顾东生,等.动员后外周血中CD34+细胞去除前后对改善肢体缺血疗效的研究.中华血液学杂志,2007,28(3):194-198
15. Holash J, Wiegand SJ, Yancopoulos GD. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF[J]. Oncogene. 1999, 18(38): 5356-5362.
16. Epstein SE, Fuchs S, Zhou YF et al. Therapeutic interventions for enhancing collateral development by administration of growth factors: basic principles, early results and potential hazards[J]. Cardiovasc Res. 2001, 49(3): 532-542.
17. Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells[J]. Science. 1999, 284(5411): 143-147.
18. Al-Khaldi A, Al-Sabti H, Galipeau J et al. Therapeutic angiogenesis using autologous bone marrow stromal cells: improved blood flow in a chronic limb ischemia model[J]. Ann Thorac Surg. 2003, 75(1): 204-209.
19. Francis S. Endothelial progenitor cells and coronary artery disease[J]. Heart. 2004, 90(6): 591-592.
20. Steiner S, Niessner A, Ziegler S et al. Endurance training increases the number of endothelial progenitor cells in patients with cardiovascular risk and coronary artery disease[J]. Atherosclerosis. 2005, 181(2): 305-310.
21. Shintani S, Murohara T, Ikeda H et al. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction[J]. Circulation. 2001, 103(23): 2776-2779.
22. Tse HF, Kwong YL, Chan JK et al. Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation[J]. Lancet. 2003, 361(9351): 47-49.
23. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor[J]. Endocr Rev. 1997, 18(1): 4-25.
24. Kamihata H, Matsubara H, Nishiue T et al. Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines[J]. Circulation. 2001, 104(9): 1046-1052.
25. Leone AM, Valgimigli M, Giannico MB, et al. From bone marrow to the arterial wall: the ongoing tale of endothelial progenitor cells[J]. Eur Heart J,2009,30(8):890-899
26. Schimieguel DM, Dominato JA, Zattar KC,et al. Does mobilization for autologous stem cell transplantation damage stromal layer formation? [J]. Hematology,2009,14(2):76-83
27. Kobayashi K, Kondo T, Inoue N, et al.Combination of in vivo angiopoietin-1 gene transfer and autologous bone marrow cell implantation for functional therapeutic angiogenesis[J]. Arterioscler Thromb Vasc Biol, 2006,26(7):1465-1472
28. Iba O, Matsubara H, Nozawa Y, Fujiyama S, Amano K, Mori Y, et al. Angiogenesis by implantation of peripheral blood mononuclear cells and platelets into ischemic limbs[J]. Circulation, 2002, 106(15):2019–2025.
29. Aicher A, Heeschen C, Mildner-Rihm C, et al. Essential role of endothelail nitrio oxide synthase for mobilization of stem and progenitor cells[J]. Nat Med, 2003, 9(11):1370-1376
30. Iwaguro H, Yamaguchi J I , Kalka C. Endothelial progenitor cells vascular endothelial growth factor transfer for vascular regeneration[J]. Circulation, 2002, 105(6):732-738.
31. Heissig B, Hattori K, Dias S, et al. Recruitment of stem and progenitor cells from the bone marrow niche reqiures MMP-9 mediaed release of kit-ligand[J]. Cell, 2002, 109(5):625-637
32. Robio SN, Pisarew VM, Chavez JM, et al. Use of matrix metallo-proteinase(MMP)-9 knockout mice demonstrates that MMP-9 activity is not absolutely required for G-CSF or Flt-3 ligandinduced hematopoietic progenitor cell mobilization or engraftment[J]. Stem cells, 2003, 21(4):417-427
33. Lebherz C, von Degenfeld G, Karl A,et al.Therapeutic angiogenesis/arteriogenesis in the chronic ischemic rabbit hindlimb: effect of venous basic fibroblast growth factor retroinfusion[J]. Endothelium, 2003, 10(4-5):257-65
34. Eric B. Staros, Innate Immune Molecular Connections Between Atherosclerosis and Statins[J].Am J Clin Pathol, 2006,125(1):8-15
1.唐博,罗文军.血栓闭塞性脉管炎发病机制的研究进展.国外医学.外科学分册, 2004, 295-298
2. Baumann G, Stangl V, Klein-Weigel P, et al. Successful treatment of thromboangiitis obliterans (Buerger's disease) with immunoadsorption: results of a pilot study. Clin Res Cardiol. 2011,100: 683-690.
3.赵文光,王嘉桔,孙思翘,等,TAO的发病变迁(百年回顾之二)[J].中国血管外科杂志(电子版),2009,2:76-78.
4.王嘉桔.TAO[J].吉林医大学报,1979,4:125- 131.
5.王嘉桔,顾亚夫,王书桂. TAO的病因学说探讨[J].吉林医学,1982,3:50- 54.
6.Shionoya S. Diagnosis criteria of Buerger’s disease[J]. Cardiol,1998,66:S243- 245.
7.Ates A, Yekeler I, Ceviz M, et al. One of the most frequent vasculardisease in northeastern of Turkey: TAO or Buerger’s disease cexperiencewith 344 cases [J]. Int J Cardiol, 2006, 111:147- 153.
8.Coaper L, Henderson SS, Ballman KV, et al. Aprospective, case controlstudy of tobacco dependence in TAO (Buerger’s disease) [J].Angiology, 2006, 57:73- 78.
9.王嘉桔. TAO的过去、现状和展望[J].普外临床,1988,3:14- 18.
10.Olin JW. TAO (Buerger’s disease) [J]. New Eng J Med, 2000,343:364- 369.
11.Hooten WM, Bruns HK, Hays TL, et al. Inpatients of sever nicotinedependence in a patient with TAO(Buerger’s disease) [J]. Mayo ClinNorth Proc, 1998, 73:529- 532.
12.Espinaza LR. Buerger’s disease: TAO 100 years after the initial description[J]. AmJ Med Sien, 2009,337:285- 286.
13.Gulati SM, Singh KS, Thusoo TK, et al. Immunological study in TAO(Buerger’s disease )[J].J Surg Res, 1979,27:287- 293.
14.Szuba A, Cooke J P. TAO: An upate on Buerger’s disease [J]. West JMed, 1998, 168:255- 260.
15.Tanaka K. Pathology and pathogenesis of Buerger’s disease[J]. Int J Cardiol, 1998,66:237- 242.
16.Mills JL. Taylor LM, Parter JM. Buerger’s disease in the modern era [J]. AmJ Surg, 1987, 154:123- 129.
17.Matsushita M, Nishikimi N, Sakaurai T, et al. Decrease in prevalence of Buerger’s disease in Japan [J]. Surgery, 1998,124:498- 502.
18.Spyridopoulos I, Sullivam AB, Kearney M, et al. Estrogen receptor mediated inhibition of human endothelial cell apoptosis. Estradiol as a survivial factor[J]. Circulation, 1997,95:1505- 1514.
19.邓靖宇,时德.雌激素对血管内皮细胞的影响及在Buerger’s病发生发展中的作用[J].中国普通外科杂志,2002,11:746- 748.
20.陆静,张丽容,刘乃丰.雌激素促进内皮生成一氧化氮的机制[J].国外医学心血管分册,2002,29:76- 78.
21.Stertinova V, Ambrozy E Stertina S, et al. 90 years of Buerger’s disease-what has changed?[J] .Brit Lek Listy, 1999,100:123- 128.
22.Sasaki S,Sakuma M, Yasuda K. Current trends in TAO(Buerger’sdisease)in women[J]. AmJ Surg, 1999,177:316- 320.
23.王宽宇,邓振鹏,孙永生,等.男性TAO性激素变化与中医型关系的研究[J].中医药学报,1995,8:36- 37.
24.于爱莲,邓文,张丰雪,等.TAO患者T细胞亚群与性激素关系的研究[J].中国实验临床免疫学杂志,1996,81:17- 19.
25.Hill GJ. The Buerger’s syndrome in Java [J].Br J Surg, 1973, 60:606- 610.
26.Malecki R, Zdrojowy K, Adamiec R. TAO in the 21ST century- A new face of disease [J] .Atheroslerosis, 2009, 206:328- 334.
27 . Mill JL. Buerger’s disease in 21STcentury:diagnosis, clinical features and therapy[J].Semin Vasc Surg,2003,16:179- 189.
28. Ohta T, Ishioashi H, Hosaka M, et al. Clinical and social consequences of Buerger disease. J Vasc Surg. 2004; 39(1):176-180.
29.徐欣,张文波,杨珏,等.膝下动脉闭塞症的腔内治疗.中国实用外科杂志, 2008, 28(10): 866- 868.
30. Liu CW, Liu B, Ye W, et al. Endovascular treatment of critical leg ischemia of arteriosclerosis obliterans. Zhongguo Yi Xue Ke Xue Yuan Xue Bao,2007, 29(1): 33- 36.
31. Black JH 3rd, LaMuraglia GM, Kwolek CJ, et al. Contemporary results of angioplasty- based infrainguinal percutaneous interventions. J Vasc Surg, 2005, 42(5): 932- 939.
32.Isner J, Asahara T. Angiogenesis and vasculogenesis a therapeutic strategies for postnatal neovascularization[J]. J Clin Invest, 1990, 103(9):1231-1236.
33. Eriko TY, Hiroaki M, Toyoaki M, et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone marrow cells: a pilot study and a randomized controlled trial [J]. The Lancet, 2002, 8(9331): 427-435.
[1] Tateish iYuyama E, M atsubara H, M urohara T, et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomized controlledtrial[J]. Lancet, 2002,360(9331):427-435.
[2] Matoba S, Tatsumi T, Murohara T, Imaizumi T, et al. Long-term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (Therapeutic Angiogenesis by Cell Transplantation [TACT] trial) in patients with chronic limb ischemia [J]. Am Heart J, 2008,156(5):1010-1018
[3] Gu Yongquan, Zhang Jian, QiI Lixing, et al. A clinical study on implantation of autologous bone marrow mononuclear cells after bone marrow stimulation for treatment of lower limb ischemia [J]. Chinese Journal of Reparative and Reconstructive Surgery, 2006,20 (10):1017-1020(In Chinese)
[4] Guo Lian rui, Gu Yong quan, Zhang Jian, et al.Rat hindlimb ischemia treated with bone marrow-derived mononuclear cell transplantation in different approaches [J]. Chinese Journal of Clinical Rehabilitation, 2005,9(10):57-59(In Chinese)
[5] Gu Yongquan, ZHANG Jian, QI Lixing, et al. Comparative study on autologous implantation between bone marrow stem cells and peripheral blood stem cells for treatment of lower limb ischemia[J]. Chinese Journal of Reparative and Reconstructive Surgery, 2007,21 (7): 675-678(In Chinese)
[6] Leone AM, Valgimigli M, Giannico MB, et al. From bone marrow to the arterial wall: the ongoing tale of endothelial progenitor cells[J].Eur Heart J, 2009,30(8):890-899
[7] Schimieguel DM, Dominato JA, Zattar KC,et al. Does mobilization for autologous stem cell transplantation damage stromal layer formation?[J]. Hematology, 2009,14(2):76-83
[8] Kobayashi K, Kondo T, Inoue N, et al.Combination of in vivo angiopoietin-1 gene transfer and autologous bone marrow cell implantation for functional therapeutic angiogenesis [J]. Arterioscler Thromb Vasc Biol, 2006,26(7):1465-1472
[9] Iba O, Matsubara H, Nozawa Y, Fujiyama S, Amano K, Mori Y, et al.Angiogenesis by implantation of peripheral blood mononuclear cells and platelets into ischemic limbs [J]. Circulation, 2002,106 (15):2019-2025.
[10] Iwaguro H , Yamaguchi J I , Kalka C. Endothelial progenitor cells vascular endothelial growth factor transfer for vascular regeneration[J].Circulation, 2002,105(6):732-738
[11] Aicher A, Heeschen C, Mildner-Rihm C, et al. Essential role of endothelail nitrio oxide synthase for mobilization of stem and progenitor cells[J]. Nat Med, 2003,9(11):1370-1376
[12] Heissig B, Hattori K, Dias S, et al. Recruitment of stem and progenitor cells from the bone marrow niche reqiures MMP-9 mediaed release of kit-ligand[J]. Cell, 2002,109(5):625-637
[13] Robio SN, Pisarew VM, Chavez JM, et al. Use of matrix metallo-proteinase (MMP)-9 knockout mice demonstrates that MMP-9 activity is not absolutely required for G-CSF or Flt-3 ligandinduced hematopoietic progenitor cell mobilization orengraftment [J]. Stem cells, 2003,21(4):417-427
[14] Lebherz C, von Degenfeld G, Karl A, et al. Therapeutic angiogenesis/arteriogenesis in the chronic ischemic rabbit hindlimb: effect of venous basic fibroblast growth factor retroinfusion [J]. Endothelium,2003,10(4-5):257-65
[15] Eric B. Staros, Innate Immune Molecular Connections Between Atherosclerosis and Statins[J]. Am J Clin Pathol, 2006,125(1):8-15
[16] Yang ZJ, Ma DC, Wang W, et al.Neovascularization and cardiomyocytes regeneration in acute myocardial infarction after bone marrow stromal cell transplantation: comparison of infarct-relative and noninfarct-relative arterial approaches in swine. Clin Chim Acta.2007;381(2):114-118.
[17] Pendyala L, Goodchild T, Gadesam RR, et al. Cellularcardiomyoplasty and cardiac regeneration.Curr Cardiol Rev. 2008;4(2):72-80.
[18]虞桂平,沈振亚,余云生,郭世强,陈一欢,胡雁秋.自体骨髓动员对急性缺血心肌血管再生的影响[J].中国组织工程研究与临床康复,2010, 14(19):3499-3502.
[19].陈婷婷,米卫东,王刚,等.粒细胞集落刺激因子促进大鼠梗死心肌的血管新生.中国修复重建外科杂志, 2010,24(10):1239-1243
[20]Benest AV, Stone OA, Miller WH, et al. Arteriolar genesis and angiogenesis induced by endothelial nitric oxide synthase overexpression results in a mature vasculature. Arterioscler Thromb Vasc Biol, 2008,28(8): 1462-1468.
[21] Comati A, Beck H, Halliday W, et al. Upregulation of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha in leptomeningeal vascular malformations of Sturge-Weber syndrome. J Neuropathol Exp Neurol, 2007, 66(1): 86-97.
[22]Arai M, Misao Y, Nagai H, Kawasaki M, Nagashima K, Suzuki K,etal.Granulocyte colony-stimulating factor: A noninvasive regeneration therapy for treating atherosclerotic peripheral artery disease.Circ J 2006; 70: 1093– 1098.
[23] Saigawa T, Kato K, Ozawa T, Toba K, Makiyama Y, Minagawa S, et al. Clinical application of bone marrow implantation in patients with arteriosclerosis obliterans,and the association between efficacy an the number of implanted bone marrow cells. Circ J 2004; 68: 1189–1193.
[24] Kinnaird T, Stabile E, Burnett MS, Shou M, Lee CW, Barr S, et al.Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation 2004; 109:1543– 1549.
[25] Rookmaaker MB, Verhaar MC, Loomans CJ, Verloop R, Peters E, Westerweel PE, et al. CD34+ cells home, proliferate, and participate in capillary formation, and in combination with CD34- cells enhance tube formation in a 3-dimensional matrix. Arterioscler Thromb Vasc Biol 2005; 25: 1843– 1850.
[26] Kamihata H, Matsubara H, Nishiue T, Fujiyama S, Amano K, Iba O, et al. Improvement of collateral perfusion and regional function by implantation of peripheral blood mononuclear cells into ischemic hibernating myocardium. Arterioscler Thromb Vasc Biol 2002; 22:1804– 1810.
[27] Qin SL, Li TS, Takahashi M, Hamano K. In vitro assessment of the effect of interleukin-1 beta on angiogenic potential of bone marrow cells. Circ J 2006; 70: 1195– 1199.
[28] Steed DL. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity ulcers. Plast Reconstr Surg 2006; 117: 143– 149.
[29] Li A, Varney ML, Valasek J, Godfrey M, Dave BJ, Singh RK. Autocrine role of interleukin-8 in induction of endothelial cell proliferation, survival, migration and MMP-2 production and angiogenesis.Angiogenesis 2005; 8: 63– 71
[30] Hermanto U,Zong CS,Wang I。H. ErbB2一overexpressing human mammary carcinoma cells display an increased requirement for llmphosphat;dylinositol 3-kinase signaling pathway in anchorage-inde-pendent growth.Oncogene.2001.20(5 1):755 1-7562.
[31] Stoica GE,Franke TF,Moroni M,et a1.Effect of estradiol on estrogen receptor_alphagene expression and activity can be modulated by the ErbB2/Pl 3-K/AM pathway.Oncogene,2003,22(39):7998-8011.
[32] Witton CJ,Reeves JR,Going JJ,et a1.Expression of the HERl-4 family of receptor tyrosine kinases in breast cancer.J Pathol,2003.200(3):290—297.
[33] Petit 1,Szyper Kravitz M,Nagler A.et a1.G-CSF induces stem cell mobilization by decreasing bone marrow SDF 1 and up-regulating CXCR4.Nat Immunol,2002.3(7):687—694.
[34] Voermans C,Kooi MI..Rodenhuis S。et at.In vitro migratory capacity of CD34+cells is related to hematopoietic recovery after autologous stem cell transplantation.Blood,2001,97(3):799～804.
2. Li G, Hu Y, Yang W, et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the DA Qing IGT and Diabetes Study. Diabetes Res Clin Pract., 2002,58:193-200.
3.范丽凤,陆菊明,郑亚光,等.糖尿病患者足溃疡的危险因素分析.中华糖尿病杂志, 2006, 14:435-437
4. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. Trans Atlantic Inter-Society Concensus (TASC). J Vasc Surg, 2000,31:S1-S296.
5. Lu D, Chen B, Liang Z, et al. Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double-blind, randomized, controlled trial.Diabetes Res Clin Pract. 2011,92:26-36.
6. Walter DH, Krankenberg H, Balzer JO, et al. Intraarterial administration of bone marrow mononuclear cells in patients with critical limb ischemia: a randomized-start, placebo-controlled pilot trial (PROVASA).Circ Cardiovasc Interv. 2011, 4:26-37.
7. Cobellis G, Botti C, Taddeo A, et al. Successful bone marrow transplantation reveals the lack of endothelial progenitor cells mobilization in a patient with critical limb ischemia: a case report. Transplant Proc. 2010 , 42:2816-2820.
8. Meng J, Yao X, Kang S, et al. Treatment of ischemic limbs by transplantation of G-CSF stimulated bone marrow cells in diabetic rabbits.Clin Invest Med. 2010, 33:E174-180.
9. Onodera R, Teramukai S, Tanaka S, et al. Bone marrow mononuclear cells versus G-CSF-mobilized peripheral blood mononuclear cells for treatment of lower limb ASO: pooled analysis for long-term prognosis.Bone Marrow Transplant. 2011, 46:278-284.
10. Sacramento CB, da Silva FH, Nardi NB, et al. Synergistic effect of vascular endothelial growth factor and granulocyte colony-stimulating factor double gene therapy in mouse limb ischemia. J Gene Med. 2010 , 12:310-319.
11. Horie T, Onodera R, Akamastu M, et al. Long-term clinical outcomes for patients withlower limb ischemia implanted with G-CSF-mobilized autologous peripheral blood mononuclear cells. Atherosclerosis. 2010 , 208:461-466.
12. Kawamoto A, Katayama M, Handa N, et al. Intramuscular transplantation of G-CSF-mobilized CD34(+) cells in patients with critical limb ischemia: a phase I/IIa, multicenter, single-blinded, dose-escalation clinical trial. Stem Cells. 2009, 27:2857-2864
1. Kanako M, Takashi S, Chiaka K, et al. Changes of mRNA Expression of Vascular Endothelial Growth Factor, Angiopoietins and Their Receptors During the Periovulatory Period in eCG/hCG-Treated Immature Female Rats. J. Exp. Zool, 2005, 303A: 590– 597
2. TateishiYuyama E, M atsubara H, M urohara T, et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomized controled trial. Lancet, 2002, 360 ( 9331) : 427-435.
3.谷涌泉,郭连瑞,张建,等.自体骨髓源干细胞移植治疗严重下肢缺血1例.中国实用外科杂志, 2003, 23 (11) : 670-670.
4.谷涌泉,张建,郭连瑞,等.骨髓动员刺激后自体骨髓源单个核细胞移植治疗下肢缺血的初步临床研究.中国修复重建外科杂志, 2006, 20(10):1017-1020.
5. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative endothelial progenitor cells for angiogenesis. Science, 1997, 275(5302): 964-967.
6. Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular function and cardiovascular risk.. N Engl J Med, 2003, 348(7): 593-600.
7. Lachmann N, Nikol S. Therapeutic angiogenesis for peripheral artery disease: stem cell therapy.Vasa, 2007, 36(4):241-251.
8. KIM, KIM, JOH, et. Angiogenesis Facilitated by Autologous Whole Bone Marrow Stem Cell Transplantation for Buerger’s Disease. StemCells ,2006,24:1194-1200;
9. Iba O, Matsubara H, Nozawa Y, Fujiyama S, Amano K, Mori Y, et al. Angiogenesis by implantation of peripheral blood mononuclear cells and platelets into ischemic limbs. Circulation,2002,106: 2019–2025.
10. Silvestre JS, Mallat Z,Duriez M,et al. Antiangiogenic effect of interleukin-10 in ischemia-induced angiogenesis in mice hindlimb. Circulation research,2000,87:448-52
1.李学东;陈剑秋.下肢动脉硬化闭塞症的腔内治疗.医学综述, 2010, 16: 882-884
2. Hoshino J, Ubara Y, Hara S, et al. Quality of life improvement and long-term effects of peripheral blood mononuclear cell transplantation for severe arteriosclerosis obliterans in diabetic patients on dialysis.Circ J. 2007, 71:1193-1198
3. Lawall H, Bramlage P, Amann B. Treatment of peripheral arterial disease using stem and progenitor cell therapy.J Vasc Surg. 2011 ,53:445-453.
4.谷涌泉,郭连瑞,张建,等.自体骨髓干细胞移植治疗严重下肢缺血1例.中国实用外科杂志2003,23:670
5. Selvin E, Erlinger T. Prevalence and risk factors for peripheral arterial disease in the Unites States: results from the national Health and Nutrition Examination Survery, 1999-2000[J].Circulation, 2004;110(6):734-738
6.李小鹰,王洁,王全义,等.周围动脉硬化闭塞症在老年血脂异常人群中的现病率调查[J].中华老年心胸血管病杂志,2005;7(1):3-6
7.刘昌伟.下肢动脉硬化闭塞症的外科治疗.临床外科杂志,2006,14(5):265-266
8. Mamode N, Scott RN. Graft type for femoro-popliteal bypass surgery[J].Cochrance Database syst Rev, 2000,(2):CD001487
9. Devine C, McCollum C. North West femoro-popliteal trial participants heparin-bonded dacron or polytetrafluorethylene for femoropopliteal bypass: five-year results of a prospective randomized multicenter clinical trial[J]. J Vasc Surg, 2004,40(5):924-931
10. Surowiec SM, Davies MG, Ebery SW, et al. Percutaneous angioplasty and stenting of the superficial femoral artery[J].J vasc surg, 2005,41(2):269-278
11. Tomita S,Mickle DA,Weisel RD,et al.Improved heart function with myogenesis and angiogenesis after autologouse porcine bone marrow stromal cell transplantation [J].J Thorac cardiovasc surg,2002,123(6):1132—1140
12. Orlic D, Kajstura j, Chimenti S, et al. Bone marrow cells regenerate infarcted myocardium[J].Nature, 2001, 410(6829):70l-705.
13. Jiang Y,Jahagirdar BN,Reinhardt RL,et a1.Pluripotency of mesenchymal stem cells derived from adult marrow[J].Nature,2002,418(6893):41-49.
14.周斌,李抒,顾东生,等.动员后外周血中CD34+细胞去除前后对改善肢体缺血疗效的研究.中华血液学杂志,2007,28(3):194-198
15. Holash J, Wiegand SJ, Yancopoulos GD. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF[J]. Oncogene. 1999, 18(38): 5356-5362.
16. Epstein SE, Fuchs S, Zhou YF et al. Therapeutic interventions for enhancing collateral development by administration of growth factors: basic principles, early results and potential hazards[J]. Cardiovasc Res. 2001, 49(3): 532-542.
17. Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells[J]. Science. 1999, 284(5411): 143-147.
18. Al-Khaldi A, Al-Sabti H, Galipeau J et al. Therapeutic angiogenesis using autologous bone marrow stromal cells: improved blood flow in a chronic limb ischemia model[J]. Ann Thorac Surg. 2003, 75(1): 204-209.
19. Francis S. Endothelial progenitor cells and coronary artery disease[J]. Heart. 2004, 90(6): 591-592.
20. Steiner S, Niessner A, Ziegler S et al. Endurance training increases the number of endothelial progenitor cells in patients with cardiovascular risk and coronary artery disease[J]. Atherosclerosis. 2005, 181(2): 305-310.
21. Shintani S, Murohara T, Ikeda H et al. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction[J]. Circulation. 2001, 103(23): 2776-2779.
22. Tse HF, Kwong YL, Chan JK et al. Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation[J]. Lancet. 2003, 361(9351): 47-49.
23. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor[J]. Endocr Rev. 1997, 18(1): 4-25.
24. Kamihata H, Matsubara H, Nishiue T et al. Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines[J]. Circulation. 2001, 104(9): 1046-1052.
25. Leone AM, Valgimigli M, Giannico MB, et al. From bone marrow to the arterial wall: the ongoing tale of endothelial progenitor cells[J]. Eur Heart J,2009,30(8):890-899
26. Schimieguel DM, Dominato JA, Zattar KC,et al. Does mobilization for autologous stem cell transplantation damage stromal layer formation? [J]. Hematology,2009,14(2):76-83
27. Kobayashi K, Kondo T, Inoue N, et al.Combination of in vivo angiopoietin-1 gene transfer and autologous bone marrow cell implantation for functional therapeutic angiogenesis[J]. Arterioscler Thromb Vasc Biol, 2006,26(7):1465-1472
28. Iba O, Matsubara H, Nozawa Y, Fujiyama S, Amano K, Mori Y, et al. Angiogenesis by implantation of peripheral blood mononuclear cells and platelets into ischemic limbs[J]. Circulation, 2002, 106(15):2019–2025.
29. Aicher A, Heeschen C, Mildner-Rihm C, et al. Essential role of endothelail nitrio oxide synthase for mobilization of stem and progenitor cells[J]. Nat Med, 2003, 9(11):1370-1376
30. Iwaguro H, Yamaguchi J I , Kalka C. Endothelial progenitor cells vascular endothelial growth factor transfer for vascular regeneration[J]. Circulation, 2002, 105(6):732-738.
31. Heissig B, Hattori K, Dias S, et al. Recruitment of stem and progenitor cells from the bone marrow niche reqiures MMP-9 mediaed release of kit-ligand[J]. Cell, 2002, 109(5):625-637
32. Robio SN, Pisarew VM, Chavez JM, et al. Use of matrix metallo-proteinase(MMP)-9 knockout mice demonstrates that MMP-9 activity is not absolutely required for G-CSF or Flt-3 ligandinduced hematopoietic progenitor cell mobilization or engraftment[J]. Stem cells, 2003, 21(4):417-427
33. Lebherz C, von Degenfeld G, Karl A,et al.Therapeutic angiogenesis/arteriogenesis in the chronic ischemic rabbit hindlimb: effect of venous basic fibroblast growth factor retroinfusion[J]. Endothelium, 2003, 10(4-5):257-65
34. Eric B. Staros, Innate Immune Molecular Connections Between Atherosclerosis and Statins[J].Am J Clin Pathol, 2006,125(1):8-15
1.唐博,罗文军.血栓闭塞性脉管炎发病机制的研究进展.国外医学.外科学分册, 2004, 295-298
2. Baumann G, Stangl V, Klein-Weigel P, et al. Successful treatment of thromboangiitis obliterans (Buerger's disease) with immunoadsorption: results of a pilot study. Clin Res Cardiol. 2011,100: 683-690.
3.赵文光,王嘉桔,孙思翘,等,TAO的发病变迁(百年回顾之二)[J].中国血管外科杂志(电子版),2009,2:76-78.
4.王嘉桔.TAO[J].吉林医大学报,1979,4:125- 131.
5.王嘉桔,顾亚夫,王书桂. TAO的病因学说探讨[J].吉林医学,1982,3:50- 54.
6.Shionoya S. Diagnosis criteria of Buerger’s disease[J]. Cardiol,1998,66:S243- 245.
7.Ates A, Yekeler I, Ceviz M, et al. One of the most frequent vasculardisease in northeastern of Turkey: TAO or Buerger’s disease cexperiencewith 344 cases [J]. Int J Cardiol, 2006, 111:147- 153.
8.Coaper L, Henderson SS, Ballman KV, et al. Aprospective, case controlstudy of tobacco dependence in TAO (Buerger’s disease) [J].Angiology, 2006, 57:73- 78.
9.王嘉桔. TAO的过去、现状和展望[J].普外临床,1988,3:14- 18.
10.Olin JW. TAO (Buerger’s disease) [J]. New Eng J Med, 2000,343:364- 369.
11.Hooten WM, Bruns HK, Hays TL, et al. Inpatients of sever nicotinedependence in a patient with TAO(Buerger’s disease) [J]. Mayo ClinNorth Proc, 1998, 73:529- 532.
12.Espinaza LR. Buerger’s disease: TAO 100 years after the initial description[J]. AmJ Med Sien, 2009,337:285- 286.
13.Gulati SM, Singh KS, Thusoo TK, et al. Immunological study in TAO(Buerger’s disease )[J].J Surg Res, 1979,27:287- 293.
14.Szuba A, Cooke J P. TAO: An upate on Buerger’s disease [J]. West JMed, 1998, 168:255- 260.
15.Tanaka K. Pathology and pathogenesis of Buerger’s disease[J]. Int J Cardiol, 1998,66:237- 242.
16.Mills JL. Taylor LM, Parter JM. Buerger’s disease in the modern era [J]. AmJ Surg, 1987, 154:123- 129.
17.Matsushita M, Nishikimi N, Sakaurai T, et al. Decrease in prevalence of Buerger’s disease in Japan [J]. Surgery, 1998,124:498- 502.
18.Spyridopoulos I, Sullivam AB, Kearney M, et al. Estrogen receptor mediated inhibition of human endothelial cell apoptosis. Estradiol as a survivial factor[J]. Circulation, 1997,95:1505- 1514.
19.邓靖宇,时德.雌激素对血管内皮细胞的影响及在Buerger’s病发生发展中的作用[J].中国普通外科杂志,2002,11:746- 748.
20.陆静,张丽容,刘乃丰.雌激素促进内皮生成一氧化氮的机制[J].国外医学心血管分册,2002,29:76- 78.
21.Stertinova V, Ambrozy E Stertina S, et al. 90 years of Buerger’s disease-what has changed?[J] .Brit Lek Listy, 1999,100:123- 128.
22.Sasaki S,Sakuma M, Yasuda K. Current trends in TAO(Buerger’sdisease)in women[J]. AmJ Surg, 1999,177:316- 320.
23.王宽宇,邓振鹏,孙永生,等.男性TAO性激素变化与中医型关系的研究[J].中医药学报,1995,8:36- 37.
24.于爱莲,邓文,张丰雪,等.TAO患者T细胞亚群与性激素关系的研究[J].中国实验临床免疫学杂志,1996,81:17- 19.
25.Hill GJ. The Buerger’s syndrome in Java [J].Br J Surg, 1973, 60:606- 610.
26.Malecki R, Zdrojowy K, Adamiec R. TAO in the 21ST century- A new face of disease [J] .Atheroslerosis, 2009, 206:328- 334.
27 . Mill JL. Buerger’s disease in 21STcentury:diagnosis, clinical features and therapy[J].Semin Vasc Surg,2003,16:179- 189.
28. Ohta T, Ishioashi H, Hosaka M, et al. Clinical and social consequences of Buerger disease. J Vasc Surg. 2004; 39(1):176-180.
29.徐欣,张文波,杨珏,等.膝下动脉闭塞症的腔内治疗.中国实用外科杂志, 2008, 28(10): 866- 868.
30. Liu CW, Liu B, Ye W, et al. Endovascular treatment of critical leg ischemia of arteriosclerosis obliterans. Zhongguo Yi Xue Ke Xue Yuan Xue Bao,2007, 29(1): 33- 36.
31. Black JH 3rd, LaMuraglia GM, Kwolek CJ, et al. Contemporary results of angioplasty- based infrainguinal percutaneous interventions. J Vasc Surg, 2005, 42(5): 932- 939.
32.Isner J, Asahara T. Angiogenesis and vasculogenesis a therapeutic strategies for postnatal neovascularization[J]. J Clin Invest, 1990, 103(9):1231-1236.
33. Eriko TY, Hiroaki M, Toyoaki M, et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone marrow cells: a pilot study and a randomized controlled trial [J]. The Lancet, 2002, 8(9331): 427-435.
[1] Tateish iYuyama E, M atsubara H, M urohara T, et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomized controlledtrial[J]. Lancet, 2002,360(9331):427-435.
[2] Matoba S, Tatsumi T, Murohara T, Imaizumi T, et al. Long-term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (Therapeutic Angiogenesis by Cell Transplantation [TACT] trial) in patients with chronic limb ischemia [J]. Am Heart J, 2008,156(5):1010-1018
[3] Gu Yongquan, Zhang Jian, QiI Lixing, et al. A clinical study on implantation of autologous bone marrow mononuclear cells after bone marrow stimulation for treatment of lower limb ischemia [J]. Chinese Journal of Reparative and Reconstructive Surgery, 2006,20 (10):1017-1020(In Chinese)
[4] Guo Lian rui, Gu Yong quan, Zhang Jian, et al.Rat hindlimb ischemia treated with bone marrow-derived mononuclear cell transplantation in different approaches [J]. Chinese Journal of Clinical Rehabilitation, 2005,9(10):57-59(In Chinese)
[5] Gu Yongquan, ZHANG Jian, QI Lixing, et al. Comparative study on autologous implantation between bone marrow stem cells and peripheral blood stem cells for treatment of lower limb ischemia[J]. Chinese Journal of Reparative and Reconstructive Surgery, 2007,21 (7): 675-678(In Chinese)
[6] Leone AM, Valgimigli M, Giannico MB, et al. From bone marrow to the arterial wall: the ongoing tale of endothelial progenitor cells[J].Eur Heart J, 2009,30(8):890-899
[7] Schimieguel DM, Dominato JA, Zattar KC,et al. Does mobilization for autologous stem cell transplantation damage stromal layer formation?[J]. Hematology, 2009,14(2):76-83
[8] Kobayashi K, Kondo T, Inoue N, et al.Combination of in vivo angiopoietin-1 gene transfer and autologous bone marrow cell implantation for functional therapeutic angiogenesis [J]. Arterioscler Thromb Vasc Biol, 2006,26(7):1465-1472
[9] Iba O, Matsubara H, Nozawa Y, Fujiyama S, Amano K, Mori Y, et al.Angiogenesis by implantation of peripheral blood mononuclear cells and platelets into ischemic limbs [J]. Circulation, 2002,106 (15):2019-2025.
[10] Iwaguro H , Yamaguchi J I , Kalka C. Endothelial progenitor cells vascular endothelial growth factor transfer for vascular regeneration[J].Circulation, 2002,105(6):732-738
[11] Aicher A, Heeschen C, Mildner-Rihm C, et al. Essential role of endothelail nitrio oxide synthase for mobilization of stem and progenitor cells[J]. Nat Med, 2003,9(11):1370-1376
[12] Heissig B, Hattori K, Dias S, et al. Recruitment of stem and progenitor cells from the bone marrow niche reqiures MMP-9 mediaed release of kit-ligand[J]. Cell, 2002,109(5):625-637
[13] Robio SN, Pisarew VM, Chavez JM, et al. Use of matrix metallo-proteinase (MMP)-9 knockout mice demonstrates that MMP-9 activity is not absolutely required for G-CSF or Flt-3 ligandinduced hematopoietic progenitor cell mobilization orengraftment [J]. Stem cells, 2003,21(4):417-427
[14] Lebherz C, von Degenfeld G, Karl A, et al. Therapeutic angiogenesis/arteriogenesis in the chronic ischemic rabbit hindlimb: effect of venous basic fibroblast growth factor retroinfusion [J]. Endothelium,2003,10(4-5):257-65
[15] Eric B. Staros, Innate Immune Molecular Connections Between Atherosclerosis and Statins[J]. Am J Clin Pathol, 2006,125(1):8-15
[16] Yang ZJ, Ma DC, Wang W, et al.Neovascularization and cardiomyocytes regeneration in acute myocardial infarction after bone marrow stromal cell transplantation: comparison of infarct-relative and noninfarct-relative arterial approaches in swine. Clin Chim Acta.2007;381(2):114-118.
[17] Pendyala L, Goodchild T, Gadesam RR, et al. Cellularcardiomyoplasty and cardiac regeneration.Curr Cardiol Rev. 2008;4(2):72-80.
[18]虞桂平,沈振亚,余云生,郭世强,陈一欢,胡雁秋.自体骨髓动员对急性缺血心肌血管再生的影响[J].中国组织工程研究与临床康复,2010, 14(19):3499-3502.
[19].陈婷婷,米卫东,王刚,等.粒细胞集落刺激因子促进大鼠梗死心肌的血管新生.中国修复重建外科杂志, 2010,24(10):1239-1243
[20]Benest AV, Stone OA, Miller WH, et al. Arteriolar genesis and angiogenesis induced by endothelial nitric oxide synthase overexpression results in a mature vasculature. Arterioscler Thromb Vasc Biol, 2008,28(8): 1462-1468.
[21] Comati A, Beck H, Halliday W, et al. Upregulation of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha in leptomeningeal vascular malformations of Sturge-Weber syndrome. J Neuropathol Exp Neurol, 2007, 66(1): 86-97.
[22]Arai M, Misao Y, Nagai H, Kawasaki M, Nagashima K, Suzuki K,etal.Granulocyte colony-stimulating factor: A noninvasive regeneration therapy for treating atherosclerotic peripheral artery disease.Circ J 2006; 70: 1093– 1098.
[23] Saigawa T, Kato K, Ozawa T, Toba K, Makiyama Y, Minagawa S, et al. Clinical application of bone marrow implantation in patients with arteriosclerosis obliterans,and the association between efficacy an the number of implanted bone marrow cells. Circ J 2004; 68: 1189–1193.
[24] Kinnaird T, Stabile E, Burnett MS, Shou M, Lee CW, Barr S, et al.Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation 2004; 109:1543– 1549.
[25] Rookmaaker MB, Verhaar MC, Loomans CJ, Verloop R, Peters E, Westerweel PE, et al. CD34+ cells home, proliferate, and participate in capillary formation, and in combination with CD34- cells enhance tube formation in a 3-dimensional matrix. Arterioscler Thromb Vasc Biol 2005; 25: 1843– 1850.
[26] Kamihata H, Matsubara H, Nishiue T, Fujiyama S, Amano K, Iba O, et al. Improvement of collateral perfusion and regional function by implantation of peripheral blood mononuclear cells into ischemic hibernating myocardium. Arterioscler Thromb Vasc Biol 2002; 22:1804– 1810.
[27] Qin SL, Li TS, Takahashi M, Hamano K. In vitro assessment of the effect of interleukin-1 beta on angiogenic potential of bone marrow cells. Circ J 2006; 70: 1195– 1199.
[28] Steed DL. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity ulcers. Plast Reconstr Surg 2006; 117: 143– 149.
[29] Li A, Varney ML, Valasek J, Godfrey M, Dave BJ, Singh RK. Autocrine role of interleukin-8 in induction of endothelial cell proliferation, survival, migration and MMP-2 production and angiogenesis.Angiogenesis 2005; 8: 63– 71
[30] Hermanto U,Zong CS,Wang I。H. ErbB2一overexpressing human mammary carcinoma cells display an increased requirement for llmphosphat;dylinositol 3-kinase signaling pathway in anchorage-inde-pendent growth.Oncogene.2001.20(5 1):755 1-7562.
[31] Stoica GE,Franke TF,Moroni M,et a1.Effect of estradiol on estrogen receptor_alphagene expression and activity can be modulated by the ErbB2/Pl 3-K/AM pathway.Oncogene,2003,22(39):7998-8011.
[32] Witton CJ,Reeves JR,Going JJ,et a1.Expression of the HERl-4 family of receptor tyrosine kinases in breast cancer.J Pathol,2003.200(3):290—297.
[33] Petit 1,Szyper Kravitz M,Nagler A.et a1.G-CSF induces stem cell mobilization by decreasing bone marrow SDF 1 and up-regulating CXCR4.Nat Immunol,2002.3(7):687—694.
[34] Voermans C,Kooi MI..Rodenhuis S。et at.In vitro migratory capacity of CD34+cells is related to hematopoietic recovery after autologous stem cell transplantation.Blood,2001,97(3):799～804.